Engflag

Esonex-DSR

Quick links to important sections

Esonex-DSR

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Esonex-DSR

What is Esonex-DSR?

Esonex-DSR is a fixed-dose combination medication primarily used for the management of gastrointestinal conditions involving excessive acid production and impaired gastric motility. It contains two active pharmacological agents: Esomeprazole and Domperidone.

Components and Mechanism

  • Esomeprazole: This component belongs to a class of drugs known as proton pump inhibitors (PPIs). It works by inhibiting the H^+/K^+-ATPase enzyme system, commonly referred to as the proton pump, located in the gastric parietal cells of the stomach lining. By blocking this system, it significantly reduces the secretion of gastric acid.
  • Domperidone: This component is a dopamine antagonist with prokinetic properties. It acts on the upper digestive tract to increase the movements or contractions of the stomach and intestines. This action facilitates the passage of food through the digestive system and helps prevent the backflow of stomach contents into the esophagus.

Therapeutic Use

The combination is typically utilized to address symptoms associated with gastroesophageal reflux disease (GERD), functional dyspepsia, and peptic ulcers. While Esomeprazole targets the chemical environment of the stomach by lowering acidity, Domperidone addresses the physical movement of the gut. Together, they aim to relieve symptoms such as heartburn, acid regurgitation, and a sense of fullness or bloating.

Regulatory References

  1. Proton Pump Inhibitors (PPI) - NIH

What side effects are possible with Esonex-DSR?

Adverse Reactions and Safety Profile

The safety profile of Esonex-DSR, a combination of Esomeprazole and Domperidone, encompasses risks associated with both active components as documented by international governmental regulatory agencies.

Common and Infrequent Adverse Reactions

Adverse events classified as Common (occurring in 1% to 10% of users) typically involve the gastrointestinal and nervous systems, and may include headache, diarrhea, abdominal pain, nausea, vomiting, and constipation. Less common reactions may involve dizziness or skin issues such as rash or itching.

Serious Adverse Reactions and Restrictions

Official regulatory documents highlight severe risks, most notably serious cardiac arrhythmias (such as QT prolongation and Torsades de Pointes) associated with the Domperidone component. Due to this risk, the medicine is contraindicated in patients with pre-existing heart conditions or when used alongside certain medications that inhibit the CYP3A4 enzyme or prolong the QT interval. Other serious documented risks include severe allergic reactions (anaphylaxis) and rare but severe cutaneous reactions (like SJS and TEN).

Duration-Related Safety Concerns

Risks that increase with the duration of use are primarily linked to the Esomeprazole component. Long-term use (typically defined as several months or more) may be associated with an increased risk of bone fractures (hip, wrist, or spine), low magnesium levels (hypomagnesemia), and potential Vitamin B12 deficiency.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Esonex-DSR overdose primarily addresses the toxicity profile of the Domperidone component. Overdose may present with serious neurological and motor manifestations. Documented clinical signs include drowsiness, disorientation, agitation, altered consciousness, and extrapyramidal reactions such as involuntary movements. Less severe, generally reversible symptoms like gastrointestinal discomfort and weakness are noted in Esomeprazole overdose summaries.

The most critical documented risks relate to the cardiovascular system. Overdose can lead to severe outcomes, including QTc interval prolongation, serious ventricular arrhythmias, and the possibility of sudden cardiac death or cardiac arrest. The risk of these severe cardiac effects is officially noted to be higher with certain high daily doses.

Immediate medical attention is required upon any suspicion of overdose. Patients must discontinue the medicine and contact emergency services immediately due to the potential for life-threatening complications. No specific antidote is known for either active substance. Management is strictly limited to symptomatic and supportive treatment, with the official regulatory constraint that ECG monitoring and close observation are necessary until all clinical signs have resolved. Extrapyramidal symptoms following overdose are documented to be more frequent in children.

Therapeutic Uses of Esonex-DSR

What Esonex-DSR Treats: Main Uses and Benefits

This medication is commonly used across conditions presenting with acute episodes of upper gastrointestinal distress, and is used in situations involving certain distressing symptoms in Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis. It is applied across domains where persistent heartburn and the backflow of sour fluid (regurgitation) create noticeable physiological strain. The primary benefit contributes to the management of symptoms related to heightened physiological activity and is relevant for easing symptoms related to inflammatory or irritative states.

The combination is particularly relevant in situations where symptoms are driven by excess acid and slow gastric emptying—symptoms associated with acute or episodic changes. This combination therapy is applied in addressing distressing symptoms related to heightened acid activity and impaired movement, including chronic nausea, abdominal bloating, and a feeling of premature fullness. It offers symptomatic relief that helps patients cope more steadily, assisting with maintaining functional stability during symptomatic periods.

The drug is also commonly used across conditions characterized by damage to the stomach or duodenal lining (Peptic Ulcer Disease) and situations involving pathological acid hypersecretion. This may assist in creating conditions relevant for the healing of damaged tissue.

Quick Facts on Therapeutic Use

Property Description
Primary Focus Acid Reflux (GERD) and Peptic Ulcers
Symptom Axis Discomfort from acid and slow digestion
Core Benefit Easing overall symptom burden and supports general well-being

Regulatory References

  1. Rwanda FDA Product Information Leaflet

Eligibility and Restrictions for Use

Esonex-DSR is a combination medicine containing esomeprazole and domperidone. Its eligibility is determined by the official restrictions for both components, primarily focusing on absolute contraindications related to cardiac and hepatic function.

Populations for Whom Use is Contraindicated

The medicine must not be used by patients with:

  • Known hypersensitivity to esomeprazole, domperidone, substituted benzimidazoles, or any excipient.
  • Existing heart conditions, including known prolongation of the QTc interval, congestive heart failure, or significant bradycardia.
  • Significant electrolyte disturbances (e.g., low potassium or magnesium) due to increased proarrhythmic risk.
  • Moderate or severe hepatic impairment (liver failure) due to the domperidone component.
  • Gastrointestinal hemorrhage, obstruction, or perforation, as motility stimulation is dangerous.
  • A prolactin-releasing pituitary tumor (prolactinoma).

Age and Physiological Restrictions

  • Children and Adolescents: Use is generally not recommended or contraindicated for children under 12 years old or those weighing less than 35 kg.
  • Older Adults (Over 60): Use requires caution due to an observed higher risk of serious ventricular arrhythmias.
  • Pregnancy and Lactation: Use during breastfeeding is not recommended or contraindicated as the drug passes into breast milk. Use during pregnancy is advised only after a medical risk-benefit analysis.

Condition-Specific Eligibility

  • Severe Renal Impairment: Requires reduced dosing frequency due to prolonged domperidone elimination.

What should I know about interactions with other medicines?

The interaction profile for Esonex-DSR is derived from the official constraints associated with its components, Esomeprazole and Domperidone. This Fixed-Dose Combination has established regulatory restrictions based on metabolic, pharmacodynamic, and absorption mechanisms.

Strictly Contraindicated Combinations

The Domperidone component is strictly contraindicated with Potent CYP3A4 Inhibitors and all QT-prolonging drugs to manage the risk of pharmacodynamic amplification, particularly severe ventricular arrhythmias. The Esomeprazole component is also strictly contraindicated with the antiretroviral Nelfinavir.

Pharmacokinetic and Absorption Alterations

The PPI component affects drug clearance and absorption. Esomeprazole reduces the exposure of the active metabolite of Clopidogrel, leading to a regulatory instruction to avoid concomitant use. Conversely, Voriconazole significantly increases Esomeprazole exposure. Substances like Rifampin and the herbal product St. John’s Wort reduce Esomeprazole plasma concentrations due to enzyme induction, and their use is likewise avoided. Esomeprazole’s elevation of gastric pH may reduce the bioavailability of drugs like Ketoconazole and Erlotinib, while increasing the exposure of Digoxin.

Procedural and Population Constraints

Due to diagnostic interference, the PPI component must be temporarily stopped at least 14 days before assessing Chromogranin A (CgA) levels. The Domperidone component is contraindicated in moderate or severe hepatic impairment.

Mechanism of Action

Esonex-DSR functions through the combined, simultaneous actions of two distinct pharmacological agents: esomeprazole and domperidone.

Esomeprazole is a proton pump inhibitor (PPI) that selectively accumulates within the acidic secretory canaliculi of the gastric parietal cells. There, it is converted to a sulfenamide intermediate which forms an irreversible covalent inhibitor complex with the H^+/ K^+-ATPase enzyme (the proton pump). This molecular interaction blocks the final step of acid secretion, resulting in a pronounced and sustained reduction in gastric lumen hydrogen ion concentration, thereby raising intragastric pH.

Domperidone is a dopamine D2 receptor antagonist that acts primarily at peripheral receptors in the gastrointestinal tract and the chemoreceptor trigger zone. Its interaction with D2 receptors in the enteric nervous system stimulates acetylcholine release. This downstream cholinergic cascade enhances the contractile force and rhythmicity of the esophageal and gastric smooth muscle, leading to increased lower esophageal sphincter pressure, accelerated gastric emptying, and overall enhanced gastrointestinal motility. The system-level consequence is modulation of both chemical and mechanical factors in the upper digestive tract.

Dosage and Administration Information

How to Use Esonex-DSR

Esonex-DSR is for oral administration as a fixed-dose combination capsule. The standard dosing regimen for adults is one capsule (Esomeprazole 40 mg / Domperidone 30 mg) taken once daily. This once-daily regimen is standardized for use across appropriate clinical scenarios.

Procedural Administration

Procedural Instruction Requirement
Timing Administer before a meal, typically 15 minutes before breakfast.
Handling The capsule must be swallowed whole with water; it must not be chewed or crushed.
Missed Dose If a dose is missed, it should be omitted, and the next scheduled dose resumed; the dose must not be doubled.
Duration Use is limited to the shortest effective duration required to control symptoms.

Adjustments for Specific Populations

Use protocols include dose adjustments or restrictions based on organ function:

  • Severe Hepatic Impairment: The combination is contraindicated due to the Domperidone component.
  • Severe Renal Impairment: The dosing frequency of the Domperidone component requires reduction.

These instructions define the protocol for using Esonex-DSR.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esonex-DSR

This overview describes the types of clinical research and scientific findings associated with Esonex-DSR, focusing on what studies have explored and the resulting research patterns, without providing medical advice or recommendations.

Evidence for Use in Reflux and Digestive Symptoms (GERD)

Research examined the combination in exploring the outcomes related to physical discomfort and outcomes related to systemic or functional imbalance associated with Gastroesophageal Reflux Disease (GERD) and related functional dyspepsia. These studies monitored changes in outcomes like heartburn, acid regurgitation, and feelings of fullness or bloating.

The evidence includes systematic reviews and randomized controlled trials (RCTs) primarily applied in studies examining patient-reported experiences among adult populations. Studies report how symptoms evolved in the observed populations over defined intervals, typically two to four weeks.

While the research contributes to understanding symptom patterns observed in short-term study contexts, data show patterns related to limited long-term information. It is not yet clear whether this fixed combination provides incremental findings or was associated with similar outcomes when compared to studies of single acid-reducing agent (PPI) therapy.

Research on Healing Endpoints (Erosive Esophagitis)

This area research describes the studies that was evaluated in settings related to the tissue resolution of damage, such as Erosive Esophagitis. The core evidence for this effect was observed in RCTs that primarily measured the degree of Endoscopic Healing Rates. Findings indicate patterns related to the Endoscopic Healing Rates that were measured during the study period. This evidence is often associated with research initially focused on the acid-suppressing component (Esomeprazole) alone.

What Remains Uncertain About Esonex-DSR Research

The evidence base still features several areas where data are still emerging or research is ongoing. A key limitation is the documented need for additional large-scale Randomized Controlled Trials (RCTs) specifically designed to evaluate the fixed combination. Additionally, follow-up durations were limited in many studies, meaning that the full characterization of long-term outcomes is not yet complete. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Esomeprazole magnesium (Oral) (Systemic) - Clinical Pharmacology
  2. Fixed-Dose Combination (FDC) of Esomeprazole and Domperidone (Examples of regulatory product information/PILs demonstrating FDC use)

Frequently Asked Questions (FAQ)

Common questions about Esonex-DSR (FAQ)

Q: What is Esonex-DSR used for?

A: Esonex-DSR is officially indicated for the management of gastroesophageal reflux disease (GERD) and peptic ulcers. It is a combination medication that helps reduce the amount of acid produced in the stomach. Regulatory documents indicate its use when a combined action is needed for these acid-related conditions.

Q: Does Esonex-DSR help with heartburn and acid reflux symptoms?

A: Yes, regulatory sources confirm that Esonex-DSR is used to address symptoms associated with GERD and peptic ulcers, which include heartburn and acid reflux. The medication works by decreasing stomach acid production, which is the primary cause of these uncomfortable symptoms. Its action is intended to provide relief from these symptoms.

Q: How long does Esonex-DSR take to start working?

A: Esonex-DSR is designed to offer a dual benefit: quick initial effect and sustained acid control. Official product information suggests that the immediate-release component of the medication can begin to work relatively soon after administration. However, full benefits for acid control may take a few days to develop.

Q: Is Esonex-DSR safe to use during pregnancy?

A: According to the official product information, limited data are available regarding the use of the components of Esonex-DSR during pregnancy. As a general caution, its use is not recommended unless a healthcare provider determines that the potential benefits clearly outweigh the potential risks. Use during pregnancy requires a careful assessment by the prescribing healthcare provider.

Q: Can I drink alcohol while taking Esonex-DSR?

A: Regulatory documents do not specifically highlight a direct, dangerous interaction between Esonex-DSR and alcohol. However, alcohol itself can irritate the stomach lining and increase acid production, which could potentially worsen the conditions the medication is intended to treat. Consulting a healthcare provider about alcohol consumption is recommended, as alcohol can worsen acid-related symptoms.

Q: What should I do if I miss a dose of Esonex-DSR?

A: Official product information provides guidance for managing a missed dose. Do not double a dose to compensate for a missed one. If a dose is forgotten, the official recommendation is to review the patient leaflet for specific instructions on when to take the next dose or to contact a healthcare provider for clarification.

Q: Can Esonex-DSR be used for a long time?

A: The official product information indicates that Esonex-DSR is generally prescribed for short-term treatment of acid-related conditions. While prolonged use may sometimes be necessary, this should not be self-initiated. Any requirement for longer-term treatment should be determined and regularly reviewed by a healthcare provider.

How should Esonex-DSR be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documentation defines strict guidelines for the storage and final disposal of Esonex-DSR (Esomeprazole/Domperidone) to ensure product stability and safety.

Storage Conditions:

Requirement Official Statement
Temperature Store below 25 C
Protection Keep in a clean and dry place
Avoidance Must be protected from direct sunlight, moisture, and heat
Safety Keep away from children and pets

Disposal Rules:

Expired or unused Esonex-DSR must be discarded properly according to official guidelines. It is explicitly stated that this medication must not be flushed in the toilet or thrown into the drain to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Esonex-DSR found in:

A-Z Index: